

Correction

Correction: Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors

In this article (Clin Cancer Res 2010;16:2352–62), which was published in the April 15, 2010, issue of *Clinical Cancer Research* (1), there was an error in the legend of Fig. 3. The corrected legend appears below.

Fig. 3. Effects of fotemustine and temozolomide in the four human uveal melanoma xenografts: MP77 (A and B), MP38 (C and D), MM26 (E and F), and MM66 (G and H). A, C, E, and G, fotemustine (●) was administered i.p. at a dose of 30 mg/kg every 3 wk. Mice in the control groups (○) received 0.2 mL of the drug-formulating vehicle with the same schedule as the treated animals. B, D, F, and H, temozolomide (■) was administered orally at a dose of 40 mg/kg day 1 to day 5 every 28 d. Mice in the control groups (□) received 0.3 mL of the drug-formulating vehicle with the same schedule as the treated animals. Treatments started when subcutaneous growing tumor volumes were 63 to 400 mm³. Tumor growth was calculated by measuring two perpendicular diameters with calipers. Tumor volume and RTV were calculated as described in Materials and Methods. Growth curves were obtained by plotting mean RTV against time. Bars, SD. Fotemustine (*n* = 8–9 mice) and corresponding fotemustine control group (*n* = 8–10 mice); Temodal (*n* = 6–10 mice) and corresponding Temodal control group (*n* = 6–10 mice).

Reference

1. Némati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, Desjardins L, Piperno-Neumann S, Lantz O, Asselain B, Plancher C, Robert D, Péguillet I, Donnadiou MH, Dahmani A, Bessard MA, Gentien D, Reyes C, Saule S, Barillot E, Roman-Roman S, Decaudin D. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res 2010;16:2352–62.

Published OnlineFirst 07/13/2010.

©2010 American Association for Cancer Research.

doi: 10.1158/1078-0432.CCR-10-1531

Clinical Cancer Research

Correction: Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors

Clin Cancer Res 2010;16:3807. Published OnlineFirst July 13, 2010.

Updated version Access the most recent version of this article at:
doi:[10.1158/1078-0432.CCR-10-1531](https://doi.org/10.1158/1078-0432.CCR-10-1531)

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/16/14/3807.2.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/16/14/3807.2>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.